Table 2.

Weighted average LVMi effect size for various cohort stratifications

StratificationNo. of CohortsSample MinSample MaxEstimated Effect Size (gm/m2)
Estimate95% CITypea
All studies237300−9.20−16.05 to −2.34R
By severity of anemia and target Hb/Hct
    severe anemia / lower target8b7153−32.73−49.37 to −16.10R
    moderate anemia / lower target6363005.26−0.80 to 11.33R
    moderate anemia / higher target823296−6.63−17.21 to 3.95R
Severe anemia/lower target by stage of kidney disease
    CKD8b911−17.57−44.66 to 9.51F
    ESRD67153−36.12−55.97 to −16.27R
Moderate anemia/lower target by stage of kidney disease
    CKD374823.89−0.67 to 8.46F
    ESRD3363006.42−5.84 to 18.67R
Moderate anemia/higher target by stage of kidney disease
    CKD374880.54−3.52 to 4.61F
    ESRD523296−11.55−32.13 to 9.04R
  • Severe anemia: Hb < 10 g/dl; moderate anemia: Hb ≥ 10 g/dl; lower target: Hb ≤ 12 g/dl; higher target: Hb > 12 g/dl.

  • a F, fixed effects estimate; R, random effects estimate.

  • b Excludes one study (Ayus et al. 2005) that did not achieve the target Hb/Hct.